Distinguished in Peptic Ulcer

Sulleman Moreea

Bradford, ENG, GB 
Distinguished in Peptic Ulcer
Bradford, ENG, GB 
OverviewLocationsClinical Research

Overview

Sulleman Moreea practices in Bradford, United Kingdom. Moreea is rated as a Distinguished expert by MediFind in the treatment of Peptic Ulcer. Their top areas of expertise are Peptic Ulcer, Gastrointestinal Bleeding, Hepatitis, Hepatitis C, and Endoscopy.

Their clinical research consists of co-authoring 23 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 3 articles in the study of Peptic Ulcer.

Locations

Bradford, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase I, Randomized, Double-blind, Placebo-controlled, Multi-centre, Ascending-dose Trial to Evaluate the Safety, Tolerability and Immunogenicity of Vaccine FP-02.2 in HBeAg-negative Hepatitis B Patients as an add-on Treatment to Entecavir or Tenofovir.
A Phase I, Randomized, Double-blind, Placebo-controlled, Multi-centre, Ascending-dose Trial to Evaluate the Safety, Tolerability and Immunogenicity of Vaccine FP-02.2 in HBeAg-negative Hepatitis B Patients as an add-on Treatment to Entecavir or Tenofovir.
Enrollment Status: Completed
Publish Date: May 22, 2025
Intervention Type: Other, Biological
Study Phase: Phase 1
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
Telaprevir in Patients With Genotype 3 HCV: Pilot Clinical Study to Evaluate Efficacy and Predictability of Therapy in Patients Who Have Failed to Respond to Pegylated Interferon and Ribavirin
Telaprevir in Patients With Genotype 3 HCV: Pilot Clinical Study to Evaluate Efficacy and Predictability of Therapy in Patients Who Have Failed to Respond to Pegylated Interferon and Ribavirin
Enrollment Status: Completed
Publish Date: January 05, 2023
Intervention Type: Drug
Study Drugs: Telaprevir, 40 Kd Pegylated interferon alfa 2a, Ribavirin
Study Phase: Phase 4
View 2 Less Clinical Trials

23 Total Publications

Hemospray® (hemostatic powder TC-325) as monotherapy for acute gastrointestinal bleeding: a multicenter prospective study.
Hemospray® (hemostatic powder TC-325) as monotherapy for acute gastrointestinal bleeding: a multicenter prospective study.
Journal: Annals of gastroenterology
Published: February 08, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Moreea's expertise for a condition
ConditionClose
    View All 7 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile